The biologics market size is projected to reach US$ 1,793.9 billion by 2031 from US$ 469.2 billion in 2023. The market is expected to register a CAGR of 18.2% in 2023–2031. Rising research and development (R&D) activities and increasing investments in biologics are likely to remain key trends in the biologics market.

Biologics Market Analysis

The increasing number of cases and diagnoses of chronic diseases requires the availability of sophisticated diagnostic and treatment drugs, which has boosted the global biologics market. Biologics are genetically modified drugs that target the specific site of inflammation, which is triggered by the immune system in response to harmful stimuli. Given the emergence of coronavirus diseases, governments in various countries also took measures to boost the healthcare industry and ensure biologics supply. In addition, researchers and scientists are studying various species and expression systems for improving the productivity of biologics. In addition, new compounds provide therapeutic options for patients who did not react to conventional treatments and demonstrated greater protection and effectiveness. Market growth is expected to be driven by the development of cell lines and reagents that increase the productivity of biologics. However, stringent regulations and high drug development costs are expected to restrain market growth.

Biologics Market Overview

The biologics market is emerging as a dynamic and promising sector within the pharmaceutical industry, offering a unique approach to treating various diseases and medical conditions. The biologics market is constantly growing because pharma and biotechnology companies spend enormously to  improve their production facilities. The geriatric population is at high risk of developing chronic diseases such as cancer and autoimmune diseases, reflecting a need for biologics and drugs for treatment. Many products in the biologics market include monoclonal antibodies (MAbs), vaccines, recombinant proteins, antisense, RNAi, molecular therapy, and more. MAbs are gaining popularity in therapeutic applications due to their specificity and effectiveness in targeting specific antigens, resulting in increased demand for biologics. Therefore, the growing demand for therapies and the preference for outsourcing are likely to provide impetus to the biologics market growth in the next few years.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Biologics Market: Strategic Insights

Biologics Market

• 
  CAGR (2023 - 2031)

  18.2%
• Market Size 2023
  US$ 469.2 Billion
• Market Size 2031
  US$ 1,793.9 Billion

Market Dynamics

GROWTH DRIVERS

• Increasing Prevalence of Chronic Diseases
• Growing Approvals For Novel Therapies

FUTURE TRENDS

• Rising Research and Development (R&D) Activities

OPPORTUNITIES

• Evolution of Biotechnology Industry in Developing Regions

Key Players

• AbbVie Inc.,
• Pfizer Inc.,
• Samsung Biologics,
• ADMA Biologics, Inc.,
• WuXi Biologics,
• Catalent, Inc,
• AGC Biologics,
• Crescendo Biologics Limited,
• Zumutor Biologics INC,
• Theriva Biologics,

Regional Overview

• North America
• Europe
• Asia-Pacific
• South and Central America
• Middle East and Africa

Market Segmentation

Product

• Monoclonal Antibodies
• Vaccines
• Recombinant Hormones/Proteins
• Cell and Gene Therapies
• Others

Application

• Cancer
• Infectious Diseases
• Autoimmune Diseases
• Others

Source

• Mammalian
• Microbial

Manufacturing

• Outsourced
• In-house

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Biologics Market Drivers and Opportunities

Increasing Prevalence of Chronic Diseases to Favor Market

According to a study titled “Chronic Disease: a Bio-Logical Approach,” published in Ellerston Capital Limited, 41 million people worldwide die from chronic diseases yearly, accounting for 74% of all deaths worldwide. Cancer alone is responsible for almost 10 million deaths in 2020, i.e., one in six deaths. According to GLOBOCAN, the number of cancer cases registered in 2020 was 19.3 million, which is estimated to rise to 24.6 million by 2030. In addition, autoimmune diseases show an annual increase in prevalence between 3% and 9%. In addition, there is a growing prevalence of neurological diseases such as Alzheimer's and Parkinson's. The prevalence of Alzheimer's disease is expected to reach 78 million in 2030 and increase to 139 million by 2050. According to the World Health Organization (WHO), every year, around 17 million people across the world succumb to death due to non-communicable diseases before the age of 70.

Researchers are increasingly seeking more specific, targeted drugs to treat chronic diseases. Biologics such as antibodies and vaccines offer more targeted treatment because they are designed to interact with the immune system in specific ways to provide treatment. In this way, biological drugs effectively treat a few chronic autoimmune diseases by blocking the overactive parts of the immune system that damage joints, skin, and other body parts. Therefore, the increasing prevalence of chronic diseases is expected to drive market growth.

Evolution of Biotechnology Industry in Developing Regions – An Opportunity for Biologics Market Growth

In modern biotechnology, antibodies are required in numerous processes, from basic research to innovative medical evaluations. The development of therapeutic antibodies has opened new avenues in treating various diseases, demonstrating the transformative ability of these particles. Antibodies are also crucial in antibody-based diagnostics as they provide accurate and reliable approaches to disease identification. Growing support from governments, rising public–private partnerships, continuously changing disease profiles, and increasing funding activities are widely enhancing the performance of biotechnology industries in the regions such as Asia Pacific, South & Central America, and the Middle East & Africa. Countries such as the UAE, Saudi Arabia, Oman, Muscat, Bahrain, Taiwan, Malaysia, India, China, Singapore, and Japan are among the most advantageous destinations for the biotechnology industry. Continuous advancements in biotechnology, genetics, and cell biology have contributed to identifying several potential therapeutics for targeted therapies. As the biotechnology industry expands scientists' toolboxes, the combination of basic research, translational studies, and clinical trials will continue to develop, investigate, and test additional compounds, techniques, and therapeutic pathways. Biotechnology is a strategic sector for China. The Made in China 2025 initiative aims to produce high-tech products, including innovative medicines. The plan introduced targets for Chinese pharmaceutical companies to spur biotechnology innovation and increase exports. Furthermore, Asian countries are more focused on using genomics, proteomics, and biomarker advancements for diagnostic and therapeutic applications. Therefore, the ongoing developments in the biotechnology industry in developing regions are expected to create opportunities for the biologics market in the coming years.

Biologics Market Report Segmentation Analysis

Key segments that contributed to the derivation of the biologics market analysis are product, application, source, and manufacturing.

• Based on product, the biologics market is divided monoclonal antibodies, vaccines, recombinant hormones/proteins, cell and gene therapy, and others. The monoclonal antibodies segment held the largest share of the market in 2023 and is anticipated to register the highest CAGR during the forecast period.
• By application, the market is segmented into cancer, infectious diseases, autoimmune diseases, and others. The cancer segment held the largest share of the market in 2023 and is anticipated to register the highest CAGR during 2023–2031.
• Based on source, the biologics market is divided into mammalian and microbial. The microbial segment held a larger share of the market in 2023. The mammalian segment is anticipated to register a higher CAGR during the forecast period.
• In terms of manufacturing, the market is bifurcated into outsourced and in-house. The outsourced segment held a larger share of the market in 2023 and is estimated to register a higher CAGR during 2023–2031.

Biologics Market Share Analysis by Geography

The geographic scope of the biologics market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.

North America has dominated the biologics market. The growth of the market in North America is because of the high prevalence of chronic diseases, numerous leading biopharmaceutical companies, favorable reimbursement policies, and significant investments in research and development. According to an article published in JAMA Network, biologics accounted for 37% of total drug spending in the US. The increasing share of prescriptions for biologics and growing investments in developing targeted drugs are contributing to the market growth. Additionally, approval of several novel biological drugs such as antisense, gene therapy, and RNAi therapeutics is expected to drive market growth further. Asia Pacific is anticipated to grow with the highest CAGR in the coming years.

Biologics Market News and Recent Developments

The biologics market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in the market for biologics:

• Samsung Biologics, a global contract development and manufacturing organization (CDMO), announced a partnership agreement with LegoChem Biosciences, a biotech company pioneering the research and development of antibody-drug conjugate (ADC) programs. Under the terms of the deal, Samsung Biologics will provide antibody development and drug substance manufacturing services as a part of LegoChem Biosciences' ADC program designed to treat solid tumors. (Samsung Biologics, Press Release, 2024)
• Selvita S.A. announced a strategic initiative to significantly expand its services portfolio and enter the field of biologic drug discovery and development by adding comprehensive therapeutic antibody discovery and development capabilities to its portfolio. (Selvita, Press Release, 2024)
• Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd, announced that the company signed a settlement and license agreement with Janssen Biotech Inc. and Johnson & Johnson (collectively known as Janssen) that clears the way to commercialize its Bmab 1200, a proposed biosimilar to Stelara, in the United States of America. (Source: Biocon, Press Release, 2023)
• Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd announced that the company completed the integration of the acquired biosimilars business from Viatris in North America (United States and Canada) effective September 1, 2023. (Source: Biocon, Press Release, 2023)
• Biodextris Inc., a subsidiary of Clean Biologics SAS, announced the development of a new industrial-scale vaccine and biologics development, manufacturing, and packaging plant (CDMO). The new facility would support companies in the development and characterization of next-generation biological products and help bridge the gap between research projects and large-scale commercial production. The project amounted to a US$ 25 million investment in indoor layout and state-of-the-art materials and equipment. (Clean Biologics, Press Release, 2023)

Biologics Market Report Scope

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Biologics Market Report Coverage and Deliverables

The “Biologics Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

• Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
• Market dynamics such as drivers, restraints, and key opportunities
• Key future trends
• Detailed PEST and SWOT analysis
• Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments
• Detailed company profiles